Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hansa Biopharma AB ( (SE:HNSA) ) has provided an announcement.
Hansa Biopharma has announced an increase in its registered share capital and number of shares and votes, following the issuance of new ordinary shares and a set-off issue. This development raises the company’s total number of registered shares and votes to 84,763,222, reflecting a strengthened capital position that could enhance its operational capabilities and market presence.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 205,049
Current Market Cap: SEK2.28B
See more data about HNSA stock on TipRanks’ Stock Analysis page.